Aurobindo Pharma transferring domestic branded generic business to subsidiary Auropharm for ₹143 cr

Aurobindo Pharma has decided to transfer its domestic branded generic pharmaceutical formulations products business to subsidiary Auropharm for a lumpsum consideration of ₹143.21 crore.

The move is in line with the strategy to further streamline and accelerate the company’s domestic business for faster growth, Aurobindo Pharma said, announcing Board approval for the transfer, on a going concern basis, and signing of a business transfer agreement (BTA) on Monday (April 6, 2026).

Auropharm (previously known as Auro Pharma) is engaged in the business of trade of branded generic formulations and pharmaceuticals products in India. The slump sale is in line with the Group’s objective to consolidate the domestic pharmaceuticals business under the subsidiary, which currently operates the non-oncology formulations business acquired from Khandelwal Laboratories. The transaction will assist the Group in expanding domestic pharmaceuticals business with greater operational efficiency, Aurobindo said.

Aurobindo Pharma’s standalone revenue for 2024-25 was ₹10,933.3 crore and the domestic branded generic formulations pharmaceuticals products business contributed ₹175.3 crore.